Defeat Duchenne Canada is committed to bringing the latest in Duchenne muscular dystrophy research and drug development to you – our Canadian Duchenne community. Complete the Registration Form below to receive the link.

Webinar Series: Industry Partner Update from Solid Biosciences

Please join Defeat Duchenne Canada and members of the Solid Biosciences team to review initial positive data from the INSPIRE DUCHENNE study of SGT-003, a next-generation microdystrophin gene therapy candidate. The Solid team will provide a current update on the study, including microdystrophin expression and biomarker results from participants who have reached the Day 90 timepoint, as well as a safety update from the first six participants dosed. In addition, they will outline plans for continued dosing in the expanded phase 1/2 study.

Solid Biosciences Webinar Participants:

• Gabriel Brooks, MD, Chief Medical Officer
• Annie Ganot, Co-founder and Head of Patient Advocacy
• Pat Gonzalez, PhD, Senior Director, Clinical Science
• Matt Harmelink, MD, Therapeutic Area Head, Neuromuscular

Complete the Registration Form below to receive the link.